Douglas M. Potter

4.9k total citations
64 papers, 3.6k citations indexed

About

Douglas M. Potter is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Douglas M. Potter has authored 64 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 22 papers in Molecular Biology and 19 papers in Immunology. Recurrent topics in Douglas M. Potter's work include Immunotherapy and Immune Responses (15 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Cancer therapeutics and mechanisms (6 papers). Douglas M. Potter is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Cancer therapeutics and mechanisms (6 papers). Douglas M. Potter collaborates with scholars based in United States, Netherlands and Switzerland. Douglas M. Potter's co-authors include Lisa H. Butterfield, Hideho Okada, Merrill J. Egorin, Ronald L. Hamilton, Ian F. Pollack, Andres Μ. Salazar, Theresa L. Whiteside, Chandra P. Belani, Ramesh K. Ramanathan and Francesmary Modugno and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Douglas M. Potter

64 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas M. Potter United States	33	1.6k	1.4k	1.4k	393	310	64	3.6k
Luis M. Vence United States	29	2.2k 1.4×	2.0k 1.4×	1.1k 0.8×	220 0.6×	215 0.7×	67	4.1k
Wolfram E. Samlowski United States	34	1.6k 1.0×	848 0.6×	1.5k 1.1×	214 0.5×	349 1.1×	154	3.7k
Marcel Deckert France	43	1.2k 0.8×	1.9k 1.3×	2.6k 1.9×	317 0.8×	705 2.3×	95	4.9k
John R. Ohlfest United States	36	1.7k 1.0×	1.5k 1.0×	1.5k 1.1×	891 2.3×	388 1.3×	65	4.2k
Andreas Lundqvist Sweden	40	2.3k 1.4×	3.2k 2.2×	1.7k 1.2×	201 0.5×	293 0.9×	148	5.3k
Begonya Comin-Anduix United States	28	2.6k 1.6×	2.1k 1.4×	1.7k 1.3×	142 0.4×	338 1.1×	42	4.3k
Trivadi S. Ganesan India	32	1.2k 0.8×	529 0.4×	1.7k 1.3×	271 0.7×	590 1.9×	166	3.8k
Alessandra Cesano United States	34	1.7k 1.1×	1.6k 1.1×	1.0k 0.7×	433 1.1×	406 1.3×	172	4.1k
Howard Streicher United States	27	1.8k 1.1×	1.2k 0.8×	910 0.7×	191 0.5×	217 0.7×	105	3.5k
Richard Burack United States	33	1.1k 0.7×	1.8k 1.2×	1.9k 1.4×	487 1.2×	187 0.6×	114	4.8k

Countries citing papers authored by Douglas M. Potter

Since Specialization

Citations

This map shows the geographic impact of Douglas M. Potter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas M. Potter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas M. Potter more than expected).

Fields of papers citing papers by Douglas M. Potter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas M. Potter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas M. Potter. The network helps show where Douglas M. Potter may publish in the future.

Co-authorship network of co-authors of Douglas M. Potter

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas M. Potter. A scholar is included among the top collaborators of Douglas M. Potter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas M. Potter. Douglas M. Potter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okada, Hideho, Lisa H. Butterfield, Ronald L. Hamilton, et al.. (2014). Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. Clinical Cancer Research. 21(2). 286–294. 83 indexed citations

Yeung, Jacky T., Ronald L. Hamilton, Koji Ohnishi, et al.. (2013). LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research. 19(7). 1816–1826. 71 indexed citations

Buren, George Van, Ramesh K. Ramanathan, Alyssa M. Krasinskas, et al.. (2013). Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma. Annals of Surgical Oncology. 20(12). 3787–3793. 36 indexed citations

Kimura, Takashi, John McKolanis, Kazi Islam, et al.. (2012). MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study. Cancer Prevention Research. 6(1). 18–26. 186 indexed citations

Sehgal, Rajesh, Barry C. Lembersky, Edward P. Balaban, et al.. (2011). A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clinical Colorectal Cancer. 10(2). 117–120. 3 indexed citations

Warin, Renaud, William H. Chambers, Douglas M. Potter, & Shivendra V. Singh. (2009). Prevention of Mammary Carcinogenesis in MMTV-neuMice by Cruciferous Vegetable Constituent Benzyl Isothiocyanate. Cancer Research. 69(24). 9473–9480. 61 indexed citations

Bao, Philip, Douglas M. Potter, David P. Eisenberg, et al.. (2009). Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB. 11(7). 606–611. 18 indexed citations

Ramalingam, Suresh S., Merrill J. Egorin, Ramesh K. Ramanathan, et al.. (2008). A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14(11). 3456–3461. 49 indexed citations

Sasaki, Kotaro, Xinmei Zhu, Fumihiko Nishimura, et al.. (2007). Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors. Cancer Research. 67(13). 6451–6458. 49 indexed citations

10.

Açılan, Ceyda, Douglas M. Potter, & William S. Saunders. (2007). DNA repair pathways involved in anaphase bridge formation. Genes Chromosomes and Cancer. 46(6). 522–531. 47 indexed citations

11.

Butterfield, Lisa H., Antoni Ribas, Douglas M. Potter, & James S. Economou. (2007). Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunology Immunotherapy. 56(12). 1931–1943. 51 indexed citations

12.

Potter, Douglas M.. (2006). Omnibus permutation tests of the association of an ensemble of genetic markers with disease in case‐control studies. Genetic Epidemiology. 30(5). 438–446. 9 indexed citations

13.

Liu, Yang, et al.. (2006). Hierarchy of α Fetoprotein (AFP)-Specific T Cell Responses in Subjects with AFP-Positive Hepatocellular Cancer. The Journal of Immunology. 177(1). 712–721. 58 indexed citations

14.

Potter, Douglas M.. (2006). Phase I Studies of Chemotherapeutic Agents in Cancer Patients: A Review of the Designs. Journal of Biopharmaceutical Statistics. 16(5). 579–604. 25 indexed citations

15.

Patel, Hitendra, Ronald G. Stoller, Miklos Auber, et al.. (2006). Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Investigational New Drugs. 24(4). 359–363. 10 indexed citations

16.

Zamboni, William C., Douglas M. Potter, Ramesh K. Ramanathan, et al.. (2005). Allometric scaling of STEALTH® liposomal anticancer agents. Cancer Research. 65. 326–326. 4 indexed citations

17.

Ramanathan, Ramesh K., Marwan Fakih, Sridhar Mani, et al.. (2005). Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemotherapy and Pharmacology. 57(4). 465–474. 12 indexed citations

18.

Ramanathan, Ramesh K., Sakkaraiappan Ramalingam, Merrill J. Egorin, et al.. (2004). Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 55(4). 354–360. 13 indexed citations

19.

Potter, Douglas M.. (2002). Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Statistics in Medicine. 21(13). 1805–1823. 23 indexed citations

20.

Potter, Douglas M.. (1981). The microchannel plate as vertex detector in high energy physics experiments. Nuclear Instruments and Methods. 184(2-3). 405–407. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact